Evidence map›Paper›PMID 42782368›Full record

ReviewCurrent rheumatology reports2026

Why Do Some Therapies Work While Others Fail? Mechanisms of Response and Emerging Treatments in axial Spondyloarthritis: 2026 SPARTAN Annual Meeting Proceedings.

Brooke J Rutledge, Lisa Wang, Mizuki Nakamura, Akihiro Nakamura

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current rheumatology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Brooke J RutledgeDepartment of Medicine, Translational Medicine Graduate Program, Queen's University, Kingston, ON, Canada.
Lisa WangFaculty of Health Sciences, School of Medicine, Queen's University, Kingston, ON, Canada.
Mizuki NakamuraLife Sciences Program, McMaster University, Hamilton, ON, Canada.
Akihiro NakamuraDepartment of Medicine, Translational Medicine Graduate Program, Queen's University, Kingston, ON, Canada. Akihiro.Nakamura@queensu.ca.ORCID http://orcid.org/0000-0002-4258-1603

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purpose of reviewThis review summarizes recent advances in the pathogenesis of axial spondyloarthritis (axSpA), examines why TNF, IL-17, and JAK inhibition is effective whereas IL-23 blockade has not demonstrated clinical efficacy, and highlights emerging therapeutic targets. RECENT

findingsTNF, IL-17 A, and IL-17 F are key drivers of inflammation in axSpA and may also contribute to pathological new bone formation. HLA-B27 can present peptides to CD8

Indexed as

Antirheumatic AgentsAxial SpondyloarthritisHLA-B27 AntigenHumansInterleukin-17Interleukin-23Janus Kinase InhibitorsTumor Necrosis Factor-alphaAntirheumatic AgentsHLA-B27 AntigenInterleukin-17Interleukin-23Janus Kinase InhibitorsTumor Necrosis Factor-alphaAxial spondyloarthritisBiTEHLA-B27IL-17JAKTNFTRBV9Type I IFN

Identifiers

PMID42782368

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.